Veronica Gambillara Fonck

Veronica is a Partner at Pureos Bioeventures since 2022. Prior to joining Pureos, Veronica co-founded LimmaTech Biologics and GlycoEra AG. She was the CEO of LimmaTech since inception (2015) until 2020 when she became CEO of GlycoEra. After GlycoEra closure of the Serie A in 2021 and the integration and transfer to a new US-based CEO in 2022, Veronica left GlycoEra to partner with Pureos. With an engineering degree and a PhD in life sciences in the field of cardiovascular disease, Veronica started her career in the MedTech field, serving roles that focused on clinical R&D and international regulatory at Endoart AG, subsequently acquired by Allergan. In 2009, after acquiring some experience in Allergan, she moved to the vaccine biotechnology field at GlycoVaxyn. Veronica held different positions from leading the clinical, regulatory department to taking care of the business development of the company. She was one of the core members responsible for building GlycoVaxyn’s success and acquisition of GSK in 2015 when she became CEO and co-founder of LimmaTech AG.